JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 4, 2008; DOI: 10.1124/jpet.108.140350


0022-3565/08/3273-941-953$20.00
JPET 327:941-953, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.108.140350v1
327/3/941    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brady, A. E.
Right arrow Articles by Lindsley, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brady, A. E.
Right arrow Articles by Lindsley, C. W.

NEUROPHARMACOLOGY

Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in RatsFormula

Ashley E. Brady, Carrie K. Jones, Thomas M. Bridges, J. Phillip Kennedy, Analisa D. Thompson, Justin U. Heiman, Micah L. Breininger, Patrick R. Gentry, Huiyong Yin, Satyawan B. Jadhav, Jana K. Shirey, P. Jeffrey Conn, and Craig W. Lindsley

Departments of Pharmacology (A.E.B., C.K.J., T.M.B., A.D.T., J.U.H., H.Y., S.B.J., J.K.S., P.J.C., C.W.L.) and Chemistry (J.P.K., M.L.B., P.R.G., H.Y., C.W.L.), Vanderbilt Program in Drug Discovery (H.Y., P.J.C., C.W.L.), Vanderbilt University Medical Center, Nashville, Tennessee

Previous clinical and animal studies suggest that selective activators of M1 and/or M4 muscarinic acetylcholine receptors (mAChRs) have potential as novel therapeutic agents for treatment of schizophrenia and Alzheimer's disease. However, highly selective centrally penetrant activators of either M1 or M4 have not been available, making it impossible to determine the in vivo effects of selective activation of these receptors. We previously identified VU10010 [3-amino-N-(4-chlorobenzyl)-4, 6-dimethylthieno[2,3-b]pyridine-2-carboxamide] as a potent and selective allosteric potentiator of M4 mAChRs. However, unfavorable physiochemical properties prevented use of this compound for in vivo studies. We now report that chemical optimization of VU10010 has afforded two centrally penetrant analogs, VU0152099 [3-amino-N-(benzo[d][1,3]dioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide] and VU0152100 [3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide], that are potent and selective positive allosteric modulators of M4. VU0152099 and VU0152100 had no agonist activity but potentiated responses of M4 to acetylcholine. Both compounds were devoid of activity at other mAChR subtypes or at a panel of other GPCRs. The improved physiochemical properties of VU0152099 and VU0152100 allowed in vivo dosing and evaluation of behavioral effects in rats. Interestingly, these selective allosteric potentiators of M4 reverse amphetamine-induced hyperlocomotion in rats, a model that is sensitive to known antipsychotic agents and to nonselective mAChR agonists. This is consistent with the hypothesis that M4 plays an important role in regulating midbrain dopaminergic activity and raises the possibility that positive allosteric modulation of M4 may mimic some of the antipsychotic-like effects of less selective mAChR agonists.


Received April 23, 2008; accepted September 3, 2008.

Address correspondence to: Professor Craig W. Lindsley, Departments of Pharmacology and Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-6600. E-mail: craig.lindsley{at}vanderbilt.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. E. Marlo, C. M. Niswender, E. L. Days, T. M. Bridges, Y. Xiang, A. L. Rodriguez, J. K. Shirey, A. E. Brady, T. Nalywajko, Q. Luo, et al.
Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity
Mol. Pharmacol., March 1, 2009; 75(3): 577 - 588.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.